News
ReveraGen BioPharma Receives $3M for Phase 2 Studies of Vamorolone in Duchenne
PPMD is thrilled to see the continued progress of VBP-15, now known as Vamorolone. Progress to date includes a first in-human study of healthy volunteers and animal data which suggests it has none of the side effects of steroids, does
More >Parent Project Muscular Dystrophy and Foundation to Eradicate Duchenne Award $1 Million Grant to ReveraGen BioPharma
Parent Project Muscular Dystrophy (PPMD) and Foundation to Eradicate Duchenne (FED) today announced that they will award ReveraGen BioPharma (ReveraGen) a $1 million grant. The grant will help fund ReveraGen’s VBP15, a
More >ReveraGen BioPharma Announces Start of Phase 1 Clinical Trial of VBP15 Dissociative Steroid Drug
ReveraGen BioPharma today announced the start of a Phase 1, first-in-human, clinical trial of a novel dissociative steroidal drug, VBP15, under development for Duchenne muscular dystrophy. Recruitment in the trial is underway, with the initial doses in the first volunteers
More >January 2015: Action Duchenne announce £55,000 funding for biomarker panel research project
We are delighted to announce that the project titled ‘Definition of pharmacodynamics biomarker panel in a Phase 2a clinical trial of VBP15 in DMD’ has successfully completed our peer-review process. The aim of this proposal is to address the increasing
More >July 2014: ReveraGen Drug Will Move to Human Testing
ReveraGen BioPharma, based in Silver Spring, Md., is moving ahead with a phase 1 trial of an experimental compound in development to treat Duchenne muscular dystrophy, made possible by a $2 million grant from U.S.-based MDA and three United Kingdom-based
More >July 2014: International Consortium Provides $2M Funding for Phase 1 Clinical Trial of ReveraGen DMD Drug
Four nonprofit organizations, the Muscular Dystrophy Association (USA), Joining Jack Foundation (UK), The Duchenne Research Fund (UK) and the Duchenne Children’s Trust (UK) have joined together to provide Phase 1 clinical trial funding for the first-in-human studies of VBP15, the
More >September 2013: VBP15 drug shows early promise for treatment of Duchenne muscular dystrophy
A preclinical study led by researchers at Children’s National Medical Center has found that a new oral drug shows early promise for the treatment of Duchenne muscular dystrophy (DMD). The results, published in EMBO Molecular Medicine, show that the drug,
More >August 2011: ReveraGen BioPharma Selected as Awardee for Inaugural National Institutes of Health’s Therapeutics for Rare and Neglected Diseases Program for its Novel Dissociative Glucocorticoid Analogue
Rockville, MD – ReveraGen BioPharma, Inc., a biopharmaceutical company developing alternatives to traditional steroid compounds, including dissociative glucocorticoid analogues for use in muscular dystrophy, has been selected by the National Institutes of Health’s (NIH) Therapeutics for Rare and Neglected Diseases
More >August 2011: Former MedImmune exec becomes CEO of startup
Under-the-radar ReveraGen BioPharma Inc., a Rockville-based biotech, has recruited former MedImmune executive Edward Connor to helm the small operation, which hopes to bring a better treatment for Duchenne muscular dystrophy to market.
More >
